Ravulizumab in treatment-naïve patients with atypical hemolytic uremic syndrome: a real-world case series
These cases highlight the importance of early diagnosis, prompt intervention, and multidisciplinary care in managing aHUS. Ravulizumab as first-line therapy proved effective and well-tolerated, with sustained clinical improvements observed across diverse real-world scenarios.
Authors
- Miriam Zacchia (ORCID: https://orcid.org/0000-0003-0376-2783)
- Rocco Baccaro (ORCID: https://orcid.org/0000-0001-8968-5592)
- Candida Iacuzzo
- Pasquale Vitale (ORCID: https://orcid.org/0009-0004-5108-7385)
- M.G. Iannuzzi
- Chiara Taglioni
- Daniela Palazzetti
- Livia Maria Sorrentino
- Floriana Secondulfo (ORCID: https://orcid.org/0000-0002-5638-0837)
- Paola Marotta
- Raffaella Sciri
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Salerno (IT)
- Agostino Gemelli University Polyclinic (IT)
- Ospedale Antonio Cardarelli (IT)
- Azienda Ospedaliera di Perugia (IT)
- Azienda Ospedaliera S.Maria (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona (IT)
Publication Details
- Journal
- Drug Target Insights
- Published
- 2025-12-09
- DOI
- https://doi.org/10.33393/dti.2025.3616
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alexion Pharmaceuticals